DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

Contributed by: Business Wire

Logo

Tags

Biotechnology

Pharmaceutical

Health

Neurology

DAYBU

More Like This

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Update on regulatory review of lecanemab for treatment of early Alzheimer's disease in the European Union

CHMP issues positive recommendation for approval of lecanemab in the EU

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU

Leqembi® (lecanemab) launched in the EU today

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors